Agalsidase alfa therapy for Fabry disease

References

• Desnick RJ, Ioannou YA, Eng CM. Alfa-galactosidase A deficiency: Fabry disease. In: The Online Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Valle D et al. (Eds). McGraw-Hill Publishing Company, Berkshire, UK (2005).
   Google Scholar
• Meikle PT, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA281, 249–254 (1999).
   PubMed Web of Science ®Google Scholar
• Kotanko P, Kramar R, Devrnja D et al. Results of a nationwide screening for Anderson–Fabry disease among dialysis patients. J. Am. Soc. Neph.15(4), 1323–1329 (2004).
   PubMed Web of Science ®Google Scholar
• Sachdev B, Takenaka T, Teraguchi H et al. Prevalence of Anderson–Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation105, 1407–1411 (2002).
   PubMed Web of Science ®Google Scholar
• Chimenti C, Pieroni M, Morgante E et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation110, 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Rolfs A, Bottcher T, Zschiesche M et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet366, 1794–1796 (2005).
   PubMed Web of Science ®Google Scholar
• MacDermot KD, Holmes A, Miners AH. Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet.38, 750–760 (2001).
   PubMed Web of Science ®Google Scholar
• MacDermot KD, Holmes A, Miners AH. Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet.38, 769–775 (2001).
   PubMed Web of Science ®Google Scholar
• Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alfa-galactosidase A activity and genetic mutations on clinical course. Medicine81, 122–138 (2002).
   PubMed Web of Science ®Google Scholar
• Beutler E, Grabowski GA. Gaucher disease. In: The Online Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Valle D et al. (Eds). McGraw-Hill Publishing Company, Berkshire, UK (2005).
   Google Scholar
• Schiffmann R, Murray GF, Treco D et al. Infusion of alfa-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl Acad. Sci. USA97, 365–370 (2000).
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human alfa-galactosidase A replacement therapy in Fabry’s disease. N. Engl. J. Med.345, 9–16 (2001).
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Kopp JB, Austin HA et al. Enzyme replacement therapy in Fabry disease: a randomized, controlled trial. JAMA285, 2743–2749 (2001).
   PubMed Web of Science ®Google Scholar
• Bishop DF, Desnick RJ. Affinity purification of alfa-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. J. Biol. Chem.256, 1307–1316 (1981).
   PubMed Web of Science ®Google Scholar
• Morimoto S, Yamamoto Y, O’Brien JS, Kishimoto Y. Distribution of saposin proteins (sphingolipid activator proteins) in lysosomal storage and other diseases. Proc. Natl Acad. Sci. USA87(9), 3493–3497 (1990).
   Google Scholar
• Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management and enzyme replacement therapy. Ann. Intern. Med.138, 338–346 (2003).
   PubMed Web of Science ®Google Scholar
• Lee K, Jin X, Zhang K et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology13(4), 305–313 (2003).
   PubMed Web of Science ®Google Scholar
• Schafer E, Baron K, Widmer U et al. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum. Mutat.25(4), 412 (2005).
   PubMedGoogle Scholar
• Beck M, Ricci R, Widmer U et al. Fabry disease: overall effects of agalsidase-alfa treatment. Eur. J. Clin. Invest.34, 838–844 (2004).
   PubMed Web of Science ®Google Scholar
• Branton MH, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J. Am. Soc. Nephrol.13, S139–S143 (2002).
   Google Scholar
• Schwarting A, Dehout F, Feriozzi S et al. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin. Nephrol.66(2), 77–84 (2006).
   PubMed Web of Science ®Google Scholar
• Beck M, Sunder-Plassmann G, Mehta A, Widmer U, Linhart A. Positive results from 3 years of enzyme replacement therapy with agalsidase-alfa in Fabry disease: data from FOS – the Fabry Outcome Survey (abstract). J. Inherit. Metab. Dis.28(Suppl. 1), 164 (2005).
   Google Scholar
• Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with aglasidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant.21, 345–354 (2006).
   PubMed Web of Science ®Google Scholar
• Baehner F, Kampmann C, Whybra C, Mieback E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a Phase IIIB study. J. Inherit. Metab. Dis.26, 617–627 (2003).
   PubMed Web of Science ®Google Scholar
• Elliott PM, Kindler H, Shah JS et al. Coronary microvascular dysfunction in male patients with Anderson–Fabry disease and the effect of treatment with alfa galactosidase A. Heart92, 357–360 (2006).
   PubMed Web of Science ®Google Scholar
• Hoffmann B, de Loenzo AG, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health-related quality of life in patients with Fabry disease: data from FOS. J. Med. Genet.42, 247–252 (2005).
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Floeter MK, Dambrosia JM et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve28, 703–710 (2003).
   PubMed Web of Science ®Google Scholar
• Moore DF, Altarescu G, Ling GSF et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke33, 525–531 (2002).
   PubMed Web of Science ®Google Scholar
• Jardim L, Vedolin L, Schwartz IVD et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J. Inherit. Metab. Dis.27, 229–240 (2004).
   PubMed Web of Science ®Google Scholar
• Dehout F, Roland D, de Granseigne S, Buillaume B, Van Maldergem L. Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease. J. Inherit. Metab. Dis.27, 499–505 (2004).
   PubMed Web of Science ®Google Scholar
• Hajioff D, Enever Y, Quiney R, Zuckerman J, Macdermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J. Inherit. Metab. Dis.26, 787–794 (2003).
   PubMed Web of Science ®Google Scholar
• Hajioff D, Hegemann S, Conti G et al. Agalsidase-alfa and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur. J. Clin. Invest.36(9), 663–667 (2006).
   PubMed Web of Science ®Google Scholar
• Eng CM, Germain DP, Banikazemi M et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet. Med.8(9), 539–548 (2006).
   PubMed Web of Science ®Google Scholar
• Wendt S, Whybra C, Kampmann C, Teichmann E, Beck M. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase-alfa. J. Inherit. Metab. Dis.28, 787–788 (2005).
   PubMed Web of Science ®Google Scholar
• Ries M, Gupta S, Moore DF et al. Pediatric Fabry disease.Pediatrics115, 344–355 (2005).
   PubMed Web of Science ®Google Scholar
• Ries M, Clarke JTC, Whybra C et al. Enzyme-replacement therapy with agalsidase-alfa in children with Fabry disease. Pediatrics118, 924–932 (2006).
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies towards agalsidase-alfa and beta. Kidney Int.66, 1589–1595 (2004).
   PubMed Web of Science ®Google Scholar
• Whitfield PD, Calvin J, Hogg S et al. Monitoring enzyme replacement therapy in Fabry disease – role of urine globotriaosylceramide. J. Inherit. Metab. Dis.28, 21–33 (2005).
   PubMed Web of Science ®Google Scholar
• Sirrs S, Nussbaumer G. Evidence supporting enzyme replacement therapy for Fabry disease is less rigorous than evidence available for other types of rare kidney diseases. J. Inherit. Metab. Dis.28(Suppl. 1), 165 (2005).
   Google Scholar
• Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease; a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine84, 261–268 (2005).
   PubMed Web of Science ®Google Scholar
• Mills K, Vellodi A, Morris P et al. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur. J. Pediatr.163, 595–603 (2004).
   Google Scholar
• Altarescu G, Hill S, Wiggs E et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J. Pediatr.138, 539–547 (2001).
   PubMed Web of Science ®Google Scholar
• Moore DF, Ries M, Forget EL, Schiffmann R. Fabry–Anderson disease: a cost–utility analysis of enzyme replacement therapy. Pharmacoeconomics (2006) (In Press).
   Google Scholar
• Pastores GM. Agalsidase-alfa: enzyme therapy for Anderson–Fabry disease. Therapy1, 203–211 (2004).
   Google Scholar
• Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol.41(Suppl. 5), 4–14 (2004).
   PubMed Web of Science ®Google Scholar